TMSP(SH:600671)2022-04-29 16:00Financial Performance - The company's operating revenue for Q1 2022 was ¥26,051,761.22, representing a decrease of 33.05% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of ¥5,826,421.39, with a diluted earnings per share of -¥0.0478[6]. - The company's net loss for Q1 2022 was ¥-171,641,624.28, worsening from ¥-165,815,202.89 in Q1 2021[26]. - The company's net profit for Q1 2022 was -7,032,712.05 RMB, compared to -3,353,092.51 RMB in Q1 2021, indicating a decline of approximately 109.5% year-over-year[30]. - Operating profit for Q1 2022 was -8,027,970.26 RMB, worsening from -5,663,210.18 RMB in the same period last year[30]. - Total revenue from sales and services received in Q1 2022 was 26,596,798.13 RMB, down from 28,074,784.98 RMB in Q1 2021, representing a decrease of about 5.3%[32]. - The company's total comprehensive loss for Q1 2022 was -7,032,712.05 RMB, compared to -3,353,092.51 RMB in Q1 2021, indicating a worsening financial position[31]. Assets and Liabilities - Total assets at the end of the reporting period were ¥390,946,508.63, down 12.89% from the end of the previous year[6]. - As of March 31, 2022, total current assets amounted to ¥178,581,862.83, a decrease from ¥186,075,275.80 at the end of 2021[24]. - The total assets as of March 31, 2022, were ¥390,946,508.63, down from ¥402,648,614.86 at the end of 2021[25]. - The total liabilities as of March 31, 2022, were ¥333,421,125.22, compared to ¥338,090,519.40 at the end of 2021[25]. - The total non-current assets as of March 31, 2022, were ¥212,364,645.80, a slight decrease from ¥216,573,339.06 at the end of 2021[25]. Cash Flow - Cash flow from operating activities showed a net outflow of ¥5,534,309.50[5]. - The net cash flow from operating activities in Q1 2022 was -5,534,309.50 RMB, compared to -1,311,785.21 RMB in Q1 2021, reflecting a significant increase in cash outflow[34]. - Cash and cash equivalents as of March 31, 2022, were ¥13,525,724.83, down from ¥22,291,090.10 at the end of 2021[24]. - Cash and cash equivalents at the end of Q1 2022 stood at 3,353,922.64 RMB, slightly up from 3,118,803.70 RMB at the end of Q1 2021[34]. - The total cash inflow from financing activities in Q1 2022 was 88,100,000.00 RMB, down from 106,840,000.00 RMB in Q1 2021[34]. Expenses - The company's sales expenses decreased by 62.78% due to the decline in revenue[11]. - The company's management expenses increased by 34.36%, primarily due to the addition of new subsidiaries[11]. - The company incurred total expenses of 56,325,393.30 RMB in operating activities during Q1 2022, compared to 34,139,489.11 RMB in Q1 2021, marking an increase of approximately 65%[34]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,823[13]. - The company reported a total shareholding of 29,000,028 shares, accounting for 23.81% of the total share capital, making it the largest shareholder[15]. Regulatory and Compliance - The company faced a fine of 1 million RMB from the China Securities Regulatory Commission for information disclosure violations[16]. - The company has a non-operating fund occupation balance of 67.2877 million RMB from previous years[16]. Investments and Development - The company is undergoing GMP renovation in two phases for its new production facility, focusing on eye drops and penicillin tablets in the first phase[19]. - The company has completed the GMP compliance inspection for its Amoxicillin Clavulanate Potassium Tablets on September 15, 2021, allowing it to resume production[19]. - The company signed a technical development contract for the consistency evaluation of its main product, with a total contract amount of 11 million RMB[19]. - The company reported a significant decrease in cash flow from investment activities, down 79.33% compared to the previous year[11]. - The company has transferred debts totaling 90 million RMB to Yongxin Huari, with 50 million RMB already received as of September 2021[18].